{
    "organizations": [],
    "uuid": "17aed8ba6970ef4f6ed271b9d8562a769998178f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-motif-bio-initiates-nda-rolling-su/brief-motif-bio-initiates-nda-rolling-submission-for-iclaprim-and-provides-business-update-idUSASC09UM6",
    "ord_in_thread": 0,
    "title": "BRIEF-Motif Bio Initiates NDA Rolling Submission For Iclaprim And Provides Business Update",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3, 2018 / 7:26 AM / Updated an hour ago BRIEF-Motif Bio Initiates NDA Rolling Submission For Iclaprim And Provides Business Update Reuters Staff \nApril 3 (Reuters) - Motif Bio PLC: \n* MOTIF BIO INITIATES NDA ROLLING SUBMISSION FOR ICLAPRIM AND PROVIDES BUSINESS UPDATE \n* INITIATION OF A ROLLING SUBMISSION OF A NEW DRUG APPLICATION (NDA) TO U.S. FOOD & DRUG ADMINISTRATION (FDA) FOR ICLAPRIM \n* NDA SUBMISSION IS EXPECTED TO BE COMPLETED DURING Q2 OF 2018. Source text for Eikon: Further company coverage:",
    "published": "2018-04-03T15:26:00.000+03:00",
    "crawled": "2018-04-03T11:35:12.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "hour",
        "ago",
        "bio",
        "initiate",
        "nda",
        "rolling",
        "submission",
        "iclaprim",
        "provides",
        "business",
        "update",
        "reuters",
        "staff",
        "april",
        "reuters",
        "motif",
        "bio",
        "plc",
        "motif",
        "bio",
        "initiate",
        "nda",
        "rolling",
        "submission",
        "iclaprim",
        "provides",
        "business",
        "update",
        "initiation",
        "rolling",
        "submission",
        "new",
        "drug",
        "application",
        "nda",
        "food",
        "drug",
        "administration",
        "fda",
        "iclaprim",
        "nda",
        "submission",
        "expected",
        "completed",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}